Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

MIF inhibitor IPG1094

An orally bioavailable inhibitor of the pro-inflammatory cytokine macrophage migration inhibitory factor (MIF), with potential anti-inflammatory, immunomodulating and antineoplastic activities. Upon oral administration, MIF inhibitor IPG1094 targets, binds to and inhibits the tautomerase activity of MIF. This attenuates the differentiation and infiltration of the immunosuppressive monocytic myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment (TME), which results in an enhanced immune response against tumor cells and the inhibition of tumor cell proliferation. MIF, overexpressed in some cancers, plays a key role in inflammation, regulation of the immune response and cancer cell proliferation. IPG1094 is able to penetrate the blood-brain barrier (BBB).
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:MIF tautomerase inhibitor IPG1094
Code name:IPG 1094
IPG-1094
IPG1094
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search